Target intelligence / Profile preview

Phosphatidylinositol 3-kinase–protein kinase B signaling pathway (PI3K–Akt signaling pathway)

Target
PI3K–Akt signaling pathway
Molecular classification
Signal transduction pathway, Intracellular signaling pathway, Contains enzyme (Kinase: PI3K), Contains enzyme (Serine/threonine kinase: Protein kinase B/Akt)
01

Overview

The **Phosphatidylinositol 3-kinase–protein kinase B signaling pathway** (PI3K–Akt pathway) is a crucial intracellular signaling cascade, highly conserved across higher eukaryotes, that plays a central role in cell survival, proliferation, growth, and metabolism. Upon activation by various growth factors, the pathway initiates at the cell membrane via activation of PI3K, which generates lipid second messengers that recruit and activate Akt (also called protein kinase B, PKB). Akt phosphorylates a multitude of substrates, altering various cellular processes including resistance to apoptosis, stimulation of cell cycle progression, and enhancement of cellular growth and metabolism. Dysregulation or hyperactivation of the PI3K–Akt pathway is strongly implicated in oncogenesis, metabolic syndromes, and resistance to targeted therapies.

Other names
PI3K–Akt pathwayPI3K-Akt signaling pathwayPhosphatidylinositol 3-kinase–Akt pathwayPI3K/AKT pathwayPKB signaling pathway
02

Mechanism of action

Inhibition of kinase activity (blocking PI3K or Akt activity directly), blocking upstream receptor activation, reducing downstream signaling for cell survival and growth, and inducing apoptosis in cancer cells by blocking survival signals.

03

Biological functions

Cell survivalCell proliferationApoptosis inhibitionCell cycle progressionMetabolism regulationAngiogenesisCell growthCell migration
04

Disease associations

Cancer (including breast, colon, brain, liver, stomach, lung, gynecological tumors)Diabetes (type 2 diabetes)Neurological/neurodegenerative diseaseCardiovascular diseaseOther proliferative and metabolic disorders
05

Safety considerations

Toxic side effects (e.g., hyperglycemia, immunosuppression)Poor selectivity with early inhibitorsDevelopment of drug resistanceOn-target metabolic effects due to pathway's ubiquitous function
06

Interacting drugs

PI3K inhibitors: idelalisib, copanlisib, duvelisib, alpelisib

2 more in the full profile.

07

Biomarkers

PIK3CA mutations (in PI3K)PTEN loss or mutationPhosphorylated Akt (p-Akt)Phosphorylated S6 (downstream of mTOR)AKT1 E17K mutation

Beyond the preview

Go deeper on Phosphatidylinositol 3-kinase–protein kinase B signaling pathway (PI3K–Akt signaling pathway).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phosphatidylinositol 3-kinase–protein kinase B signaling pathway (PI3K–Akt signaling pathway).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call